AMENDED CLAIMS

received by the International Bureau on 02 February 2015 (02.02.2015)

Condensed pyrimidine compounds of general formula (I)

in which

G is a phenyl optionally substituted with at least one substituent Z or a 5- to 10-membered heteroaryl optionally substituted with at least one substituent Z;

Z independently of one another is ((C CeJ-alkyl, (C C₆)-hydroxyalkyl, (CrC^-alkoxy, (C C₆)- haloalkyl, halogen, hydroxyl or cyano, wherein aforementioned alkyls are branched or straight-chain and can be substituted;

R is (C C₄)-alkyl, (C C₄)-alkoxy, (C₃-C₆)-cycloalkyl, S(0)_x(d-C₄)-alkyl or (Ci-C₄)-alkyl-S(0)_x(C C₄)alkyl; if the structural element represents a double bond, then R² stands for hydrogen, (C C₄)- alkyl, SiOMC C^-alkyl or (C₁-C₄)-alkyl-S(0)_x(C₁-C₄)alkyl; if the structural element represents a single bond, then R² stands for R^2a and R² which are independently of each other hydrogen, (C_rC₄)-alkyl, SiO^C a -alkyl or (C C₄)-alkyl- S(0)_x(C C₄)alkyl, under the proviso that only one of R^2a and R² is S(0)_x(C C₄)-alkyl or (C C₄)-alkyl-S(0)_x(C C₄)alkyl at the same time, or wherein R^2a and R^2b together with the carbon atom to which they are bound form a 3- to 6-membered saturated or unsaturated carbocycle or a 3- to 6-membered heterocycle containing at least one heteroatom selected from O, N and S wherein the sulphur atom may be oxidized to form a chemical grouping SO or S0₂; x is 0, 1 , or 2;

Q is phenyl substituted with a substituent X¹ and optionally with at least one substituent X;

X¹ is selected from the following chemical groupings L-C0₂R³, 0-L-C0₂R³, O-L-COR⁴, NH-L- C0₂R³, and N((C C₄)-alkyl)-L-C0₂R³;

R³ is hydrogen or (Ci-C₆)-alkyl;

R⁴ is NH₂, NHR⁵, NR⁵R⁶, whereas 71

R⁵ and R⁶ independently of one another is (C C₆)-alkyl, (C₁-C₆)-hydroxyalkyl, (C₃-C₆)-cycloalkyl, (C C )-alkyl-(C3-C₆)-cycloalkyl, or a 3-to 6-membered heterocycle having at least one heteroatom selected from nitrogen, oxygen or sulphur, or

R⁵ and R⁶, together with the nitrogen atom to which they are bound, form a saturated 3- to 6- membered heterocycle, which optionally contains at least one further heteroatom selected from nitrogen, oxygen or sulphur, and which heterocycle can be substituted with at least one substituent selected from branched or straight-chain (Ci-C₆)-alkyl or hydroxyl;

L is a bond, a branched or straight-chain (d-C -alkyl or (C₂-C )-alkenyl group, which alkyl or alkenyl groups may be substituted with at least one substituent selected from (CrC^-alkyl, (C₃- C₆)-cycloalkyl, (C C₆)-alkoxy, (C₃-C₆)-cycloalkoxy, (C C₆)-haloalkyl, (⁽-VC^-haloalkoxy, halogen, hydroxyl, amino or cyano; and

X independently of one another is (C C₆)-alkyl, (C₃-C₆)-cycloalkyl, (C C₆)-alkoxy, (C₃-C₆)- cycloalkoxy, (C C₆)-haloalkyl, (C C₆)-haloalkoxy, halogen, hydroxyl, cyano, carboxyl, -NH₂, - H^ ^-alkyl, -N((C C₆)-alkyl)2, N-pyrrolidinyl, N-piperidinyl, N-morpholinyl, - NH-C(0)-(C_rC₆)-alkyl, -C(0)-NH₂, -C(0)-NH(C C₆)-alkyl, -C(0)-N((C C₆)-alkyl)₂, -S(0)₂-NH_2, - S(Ci-C₆)-alkyl, -S(0)-(C C₆)-alkyl, or -SiO^C ^-alkyl, wherein the aforementioned alkyl chains are branched or straight-chain and can be substituted; as well as pharmacologically tolerable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof.

The condensed pyrimidine compounds according to claim 1 , wherein

G is selected from phenyl, thienyl, furanyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridiyl, pyrimidinyl, benzofuranyl, benzodioxazolyl, benzothiazolyl, quinolinyl, benzodioxazolyl.

The condensed pyrimidine compounds according to claim 1 , wherein is selected from the following groups G1 to G39

72

in which the site marked with an asterisk (*) indicates the inding s te at posi on o

ring; and k is 0, 1 , 2, 3, 4, 5, 6.

The condensed pyrimidine compounds according to claim 3, wherein

G is selected from G1 , G2, G3, G4, G5, G6, G7, G8, G9, G10, G1 1 , G12, G13, G14, G15, G16, G17, G26, G27, G28, G34, G35, G36, G37 and G38;

Z independently of one another is (C C₄)-alkoxy, CI, F, Br, (d-C^-alkyl, (C C₄)-haloalkyl, (C C₄)-haloalkoxy, S(C C₄)-alkyl, SO(C C₄)-alkyl, S0₂(C_rC₄)-alkyl;

Q is a phenyl substituted with a substituent X¹ and optionally with at least one substituent X. The condensed pyrimidine compounds according to any one of claims 1 to 4, wherein

Q is selected from the following groups Q1 to Q15, in which the site marked with an asterisk indicates the binding site at the nitrogen atom;

73

p is 0, 1 , 2, 3 or 4;

R³ is hydrogen or methyl or ethyl;

R⁴ is NH₂, NHCH₃, N(CH₃)₂, NHC₂H₅, NHCH(CH₃)₂, NHCH₂CH₂OH or one of the following groups R -1 to R -9

R⁴-6 R⁴-7 R⁴-8 R⁴-9

The pyrimidine compounds according to any one of claims 1 to 5 having the following general formula (l-A)

74 wherein G, R¹, R² and Q are as defined in any one of claims 1 to 5.

7. The pyrimidine compounds according to any one of claims 1 to 5 having the following general formula (l-B)

wherein G, R¹, R^2a, R^2b and Q are as defined in any one of claims 1 to 5.

8. The pyrimidine compounds according to claim 7 having one of the following general formulae (l-B-1), (l-B-2) or (l-B-3)

wherein G, R¹ and Q are as defined in any one of claims 1 to 5; n stands for 1 , 2, 3, or 4; n' stands for 1 , 2, or 3;

V stands for N or S(0)x';

W stands for 0, N, or S(0)x'; x' is 0, 1 , or 2.

Medicament containing at least one compound as defined in one of claims 1 to 8.

0. The compounds as defined in one of claims 1 to 8 in the presented form or in the form of their acids or bases or in the form of the physiologically tolerable salts, or in the form of their solvates, optionally in the form of their racemates, their pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio for use as a medicament for the treatment of conditions or diseases selected from the following rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, gout, osteoarthritis, psoriasis, atopic dermatitis, lichen planus, uveitis, Crohn's disease, ulcerative colitis, and acute and chronic inflammations of the gall bladder and bile ducts, of pseudopolyps and juvenile polyps, systemic lupus erythematosus, lupus nephritis, chronic prostatitis, interstitial cystitis, benign prostatic hyperplasia, COPD, chronic bronchitis, asthma, pulmonary fibrosis, allergic and non-allergic rhinitis, obstructive sleep apnoea, cystic fibrosis, chronic sinusitis, emphysema, cough, alveolitis, acute respiratory distress syndrome, pulmonary oedema, bronchiectasis, pneumonia, hepatic fibrosis, systemic sclerosis, scleroderma, cancers, haematopoietic cancers, B-cell lymphoma, T-cell lymphoma, chronic lymphatic and chronic myeloid leukaemia, acute lymphatic and acute myeloid leukaemia, and gliomas, type 2 diabetes, metabolic syndrome, obesity/adiposity, fatty liver disease (not alcohol-induced), and cardiovascular diseases, in particular arteriosclerosis, pulmonary arterial hypertension, schizophrenia, depression, bipolar or manic depression, dementia, memory loss, generalised anxiety disorder, Parkinson's disease, multiple sclerosis, Alzheimer's disease, stroke, amyotrophic lateral sclerosis.

The compounds for use as a medicament according to claim 10, wherein the conditions or diseases are selected from the following group: inflammatory diseases of the joints, skin and eyes, gastrointestinal diseases and complaints, inflammatory diseases of the internal organs; hyperplastic diseases, respiratory or lung diseases associated with elevated mucus production, inflammation and/or obstruction of the respiratory tract, diseases of the fibrotic spectrum, cancers, metabolic diseases, psychological disorders, and diseases of the peripheral or central nervous system.